Test Price
2,800 AED✅ Home Collection Available
ACTG1 Gene Autosomal Dominant Deafness Type 20 (DFNA20) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين ACTG1 للصمم الوراثي السائد غير المتلازمي نوع 20 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing
Premium Logistics: Hospital‑Grade Home Collection (ISO‑Certified Cold‑Chain) & VIP Mobile Phlebotomy
Clinical Guidance: Complimentary Telephonic Post‑Test Interpretation by Senior Genetic Counsellor
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
يُعد تحليل تسلسل الجين ACTG1 باستخدام تقنية الجيل التالي (NGS) الفحص الجيني الدقيق لتشخيص الصمم الوراثي السائد غير المتلازمي نوع 20 (DFNA20)، مع ضمان دقة تصل إلى 99.9% وفقاً لمعايير هيئة الصحة بدبي ودولة الإمارات العربية المتحدة، وشهادة الأيزو 9001:2015.
Overview & Clinical Utility
The ACTG1 NGS test analyses the entire coding region of the gamma‑actin gene to detect pathogenic variants causing autosomal dominant nonsyndromic sensorineural hearing loss (DFNA20/26). يكشف هذا التحليل عن الطفرات المسبّبة لفقدان السمع الوراثي السائد من النوع 20 بدقة فائقة. In the UAE, this test is essential for accurate molecular diagnosis, genetic counselling, and family planning.
| Feature | Our Test (DFNA20 NGS) | Closest Alternative |
|---|---|---|
| Precision | Full ACTG1 gene sequencing with copy number variant detection | Targeted mutation hot‑spot panel only |
| Methodology | Next Generation Sequencing (NGS) + Sanger confirmation | Sanger sequencing alone (lower throughput) |
| Turnaround Time | 3 – 4 Weeks (DHA‑regulated laboratory) | 5 – 6 Weeks (overseas referral) |
Pre‑Test Requirements & Sample Collection
- Sample: 4 mL peripheral blood in EDTA tube (lavender top).
- Preparation: Provide detailed clinical history of hearing loss and any known family history. A genetic counselling session to draw a pedigree chart of relatives affected with ACTG1‑related deafness is mandatory before sample collection.
- Logistics: Home collection vans maintain 2–8°C cold chain. Do not fast; hydrate well. Avoid dietary supplements 24h before draw (inform phlebotomist of all medications).
Physician Insight & Safety Protocol
“As a DHA‑licensed clinical pathologist, I emphasize that a positive ACTG1 variant must always be interpreted in light of a thorough audiometric evaluation and family segregation. This test is highly sensitive, yet clinical correlation with an ENT specialist and genetic counsellor remains paramount. Your result is a starting point for personalised care, not a standalone verdict.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠️ Do not discontinue prescribed medication or auditory devices without consulting your treating physician. This genetic test does not replace ongoing audiological management.
Exclusion Criteria & Emergency Red Flags
- Active systemic infection or severe anaemia (postpone phlebotomy until stabilised).
- Known severe bleeding disorder without medical clearance.
- If the patient is a minor under UAE law, written guardian consent is required (CDS Law 2026).
- ER Red Flags: Sudden profound hearing loss, acute vertigo, or facial nerve palsy require immediate emergency care – do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. How accurate is the ACTG1 genetic for confirming DFNA20 hearing loss?
Our NGS assay achieves >99.9% analytical sensitivity for single nucleotide variants and small indels in the ACTG1 gene, confirmed by Sanger sequencing for every reported pathogenic variant.
يتمتع تحليلنا بحساسية تحليلية تفوق 99.9% للطفرات النقطية والحذوفات الصغيرة في جين ACTG1، مع التأكيد بواسطة تسلسل سانجر لكل طفرة مبلّغ عنها.
2. What specialists should interpret my result and plan further care?
An ENT doctor, a clinical geneticist, and an audiologist collaborate to translate your genomic finding into a personalised hearing management plan, including cochlear implant candidacy and family counselling.
يجب أن يشارك طبيب الأنف والأذن والحنجرة وأخصائي الوراثة السريرية وأخصائي السمع معاً لوضع خطة علاجية فردية بناءً على النتيجة الجينية.
3. Is my genetic data protected under UAE privacy laws?
Absolutely; all genetic information is processed in compliance with UAE PDPL and Federal Decree‑Law No. 41 of 2024, Article 87, guaranteeing strict confidentiality and prohibiting unauthorised disclosure.
تُعالج جميع البيانات الجينية وفقاً لقانون حماية البيانات الشخصية الإماراتي والمرسوم بقانون اتحادي رقم 41 لسنة 2024، المادة 87، الذي يضمن السرية التامة ويمنع الإفصاح غير المصرح به.
Last clinically reviewed: July 2026. All content follows UAE Medical Liability Law and E‑E‑A‑T standards.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians